Literature DB >> 32147752

Review of Secondary Causes of Osteoporotic Fractures Due to Diabetes and Spinal Cord Injury.

Ariane Zamarioli1, Caio de Andrade Staut2, José B Volpon3.   

Abstract

PURPOSE OF REVIEW: The aim of this review is to gain a better understanding of osteoporotic fractures and the different mechanisms that are driven in the scenarios of bone disuse due to spinal cord injury and osteometabolic disorders due to diabetes. RECENT
FINDINGS: Despite major advances in understanding the pathogenesis, prevention, and treatment of osteoporosis, the high incidence of impaired fracture healing remains an important complication of bone loss, leading to marked impairment of the health of an individual and economic burden to the medical system. This review underlines several pathways leading to bone loss and increased risk for fractures. Specifically, we addressed the different mechanisms leading to bone loss after a spinal cord injury and diabetes. Finally, it also encompasses the changes responsible for impaired bone repair in these scenarios, which may be of great interest for future studies on therapeutic approaches to treat osteoporosis and osteoporotic fractures.

Entities:  

Keywords:  Bone loss; Diabetes; Osteoporosis; Osteoporotic fractures; Spinal cord injury

Year:  2020        PMID: 32147752     DOI: 10.1007/s11914-020-00571-w

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  2 in total

1.  Spinal Cord Injury: The Global Incidence, Prevalence, and Disability From the Global Burden of Disease Study 2019.

Authors:  Weizhong Ding; Shian Hu; Pengju Wang; Honglei Kang; Renpeng Peng; Yimin Dong; Feng Li
Journal:  Spine (Phila Pa 1976)       Date:  2022-06-30       Impact factor: 3.241

2.  Expression of lncRNA MALAT1 through miR-144-3p in Osteoporotic Tibial Fracture Rats and Its Effect on Osteogenic Differentiation of BMSC under Traction.

Authors:  Shiyong Ling; Tao Xu; Jingchuan Sun; Chen Yan; Bo Lv; Hua Wang; Hong Zhao; Kai Huang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-05       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.